Literature DB >> 19299716

Ncf1 provides a reactive oxygen species-independent negative feedback regulation of TLR9-induced IL-12p70 in murine dendritic cells.

Cornelia Richter1, Martina Herrero San Juan, Jutta Will, Ralf P Brandes, Ulrich Kalinke, Shizuo Akira, Josef M Pfeilschifter, Malin Hultqvist, Rikard Holmdahl, Heinfried H Radeke.   

Abstract

Permanent exposure to pathogens requires decisions toward tolerance or immunity as a prime task of dendritic cells. The molecular mechanisms preventing uncontrolled immune responses are not completely clear. We investigated the regulatory function of Ncf1, an organizing protein of NADPH oxidase, in the signaling cascade of Toll-like receptors. TLR9-stimulated spleen cells from both Ncf1-deficient and B10.Q mice with a point mutation in exon 8 of Ncf1 exhibited increased IL-12p70 secretion compared with controls. This finding was restricted to stimulatory CpG2216 and not induced by CpG2088. Because only CpG/TLR9-induced IL-12p70 was regulated by Ncf1, we used TRIF(-/-) and MyD88(-/-) cells to show that TLR9/MyD88 was primarily affected. Interestingly, additional experiments revealed that spleen cells from NOX2/gp91(phox)-deficient mice and the blocking of electron transfer by diphenylene iodonium had no influence on CpG-induced IL-12p70, confirming an NADPH oxidase-independent function of Ncf1. Finally, proving the in vivo relevance CpG adjuvant-guided OVA immunization resulted in a strong augmentation of IL-12p70-dependent Th1 IFN-gamma response only in Ncf1-deficient mice. These data suggest for the first time an important role for Ncf1 in the fine tuning of the TLR9/MyD88 pathway in vitro and in vivo that is independent of its role as an activator of NOX2.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19299716     DOI: 10.4049/jimmunol.0800795

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Dysregulated TLR3-dependent signaling and innate immune activation in superoxide-deficient macrophages from nonobese diabetic mice.

Authors:  Maria C Seleme; Weiqi Lei; Ashley R Burg; Kah Yong Goh; Allison Metz; Chad Steele; Hubert M Tse
Journal:  Free Radic Biol Med       Date:  2012-02-04       Impact factor: 7.376

2.  NADPH Oxidase-Derived Superoxide Provides a Third Signal for CD4 T Cell Effector Responses.

Authors:  Lindsey E Padgett; Hubert M Tse
Journal:  J Immunol       Date:  2016-07-29       Impact factor: 5.422

3.  p47(phox) directs murine macrophage cell fate decisions.

Authors:  Liang Yi; Qi Liu; Marlene S Orandle; Sara Sadiq-Ali; Sherry M Koontz; Uimook Choi; Fernando J Torres-Velez; Sharon H Jackson
Journal:  Am J Pathol       Date:  2012-01-02       Impact factor: 4.307

4.  NADPH oxidase-2 derived ROS dictates murine DC cytokine-mediated cell fate decisions during CD4 T helper-cell commitment.

Authors:  Meghan A Jendrysik; Sam Vasilevsky; Liang Yi; Adam Wood; Nannan Zhu; Yongge Zhao; Sherry M Koontz; Sharon H Jackson
Journal:  PLoS One       Date:  2011-12-01       Impact factor: 3.240

5.  Defective IL-23/IL-17 Axis Protects p47phox-/- Mice from Colon Cancer.

Authors:  Cornelia Richter; Martina Herrero San Juan; Benno Weigmann; Dominik Bergis; Katrin Dauber; Michael H Muders; Gustavo B Baretton; Josef Martin Pfeilschifter; Halvard Bonig; Sebastian Brenner; Heinfried H Radeke
Journal:  Front Immunol       Date:  2017-01-27       Impact factor: 7.561

6.  Neutrophil Cytosolic Factor 1 in Dendritic Cells Promotes Autoreactive CD8+ T Cell Activation via Cross-Presentation in Type 1 Diabetes.

Authors:  Chao Liu; Robert L Whitener; Andrea Lin; Yuan Xu; Jing Chen; Alexei Savinov; Jennifer W Leiding; Mark A Wallet; Clayton E Mathews
Journal:  Front Immunol       Date:  2019-05-01       Impact factor: 7.561

7.  PP2A-dependent control of transcriptionally active FOXO3a in CD8(+) central memory lymphocyte survival requires p47(phox).

Authors:  Q Liu; L Yi; S Sadiq-Ali; S M Koontz; A Wood; N Zhu; S H Jackson
Journal:  Cell Death Dis       Date:  2012-08-23       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.